Prosecution Insights
Last updated: November 12, 2026
Application No. 18/774,670

Inducible AAV REP genes

Final Rejection §112§DP
Filed
Jul 16, 2024
Priority
Sep 19, 2017 — EU 17001562.2 +3 more
Examiner
GILL, RACHEL B
Art Unit
1671
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Cevec Pharmaceuticals GmbH
OA Round
2 (Final)
66%
Grant Probability
Favorable
3-4
OA Rounds
94%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allowance Rate
584 granted / 889 resolved
+5.7% vs TC avg
Strong +29% interview lift
Without
With
+28.6%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
49 currently pending
Career history
941
Total Applications
across all art units

Office Action

§112 §DP
DETAILED ACTION Disposition of Claims Claims 1-16 remain pending. Amendments to claims 1-8 and 11-16 are acknowledged and entered. Examiner’s Note The paragraph numbers regarding the instant disclosure, unless otherwise noted, are from the PGPub of the instant application, US20250011813A1, Pub. 01/09/2025. Applicant is encouraged to utilize the new web-based Automated Interview Request (AIR) tool for submitting interview requests; more information can be found at https://www.uspto.gov/patent/laws-and-regulations/interview-practice. Optional Authorization to Initiate Electronic Communications The Applicant’s representative may wish to consider supplying a written authorization in response to this Office action to correspond with the Examiner via electronic mail (e-mail). This authorization is optional on the part of the Applicant’s representative, but it should be noted that the Examiner may not initiate nor respond to communications via electronic mail unless and until Applicant’s representative authorizes such communications in writing within the official record of the patent application. A sample authorization is available at MPEP § 502.03, part II. If Applicant’s representative chooses to provide this authorization, please ensure to include a valid e-mail address along with said authorization. Response to Arguments Applicant's arguments filed 07/27/2026 regarding the previous Office action dated 04/29/2026 have been fully considered. If they have been found to be persuasive, the objection/rejection has been withdrawn below. Likewise, if a rejection/objection has not been recited, said rejection/objection has been withdrawn. If the arguments have not been found to be persuasive, or if there are arguments presented over art that has been utilized in withdrawn rejections but utilized in new rejections, the arguments will be addressed fully with the objection/rejection below. Nucleotide and/or Amino Acid Sequence Disclosures (Objection withdrawn.) The objection to the specification due to sequence disclosures is withdrawn in light of the amendments to claim 2. Claim Rejections - 35 USC § 112(b); Second Paragraph The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. (Rejection maintained in part.) Claim 1 and dependent claims 2-16 thereof under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, is maintained in part and withdrawn in part in light of applicant’s arguments. The term “the functionality of said Rep78 and Rep68 proteins is maintained” in claim 1 is a relative term which renders the claim indefinite. The term “functionality is maintained” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. While the specification attempts to define this term at ¶[0015], the Rep78 and Rep68 proteins have multiple functions (e.g. viral replication (bind to ITRs, catalyze formation of dsDNA), site-specific integration, endonuclease activity, helicase and ATPase activity, transcriptional regulators, and cell cycle interference) and Rep78 has also been shown to interact with and inhibit cellular protein kinases such as PRKX and PKA. It is unclear if the definition provided for at ¶[0015] is intended to measure one of these functions, a subset of functions, or all functions to determine if said functionality has been “maintained” or not. Further, it is not clear how said functionality is measured, especially for each specific function noted. Since a skilled artisan would not be reasonably apprised as to the metes and bounds of the claimed invention, instant claim 1 is rejected on the grounds of being indefinite. Claims 2-16 are also rejected since they depend from claim 1, but do not remedy these deficiencies of claim 1. Response to Arguments Applicant's arguments filed 07/27/2026 have been fully considered but they are not entirely persuasive. While the rejection regarding the definition of the mutations has been withdrawn in light of applicant’s arguments, the rejection regarding the functionality limitation being indefinite is maintained. Applicant’s arguments regarding the limitation “the functionality of said Rep78 and Rep68 proteins is maintained” have been considered and are not persuasive. Applicant relies upon ¶[0015], which stated that maintaining functionality refers to mutations that do not reduce the “functional activity” of Rep78 and Rep68, or reduce such activity by at most 30%. However, this definition does not resolve the indefiniteness because it does not identify what “functional activity” is to be measured in determining whether the claim limitation is satisfied. Rep78 and Rep68 possess multiple distinct biological and biochemical functions, including DNA binding, site-specific endonuclease activity, ATPase activity, helicase activity, functions in AAV genome replication, and transcriptional regulatory activity. ¶[0015] does not specify whether “functional activity” refers to one particular activity, all activities, a combination of activities, or another measure of Rep78/Rep68 function. Accordingly, a nucleic acid mutation could preserve one Rep78/Rep68 activity within 30% of a reference value while substantially impairing another, and the claim does not establish whether such an embodiment falls within or outside the scope of claim 1. The examples do not provide an objective boundary sufficient to resolve this ambiguity. Although example 4 evaluates functionality by demonstrating AAV particle production and comparing AAV titers to control constructs, the specification does not state that AAV production or AAV titer constitutes the “functional activity” referenced at ¶[0015], nor does ¶[0015] identify the assay, reference condition, or activity to which the recited 30% reduction is to be applied. Further, it is unclear whether the required functionality must be maintained independently for both Rep78 and Rep68. Accordingly, while ¶[0015] provides a numerical degree of allowable reduction, it does not provide a sufficiently definite standard for determining what activity is being measured and, therefore, does not reasonably apprise one of ordinary skill in the art of the metes and bounds of what is being claimed. (Rejection withdrawn.) The rejection of Claims 2 and 14-16 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, is withdrawn in light of the amendments to the claims. (Rejection withdrawn.) The rejection of Claims 5-7 and 9-10 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, is withdrawn in light of the amendments to the claims. (Rejection withdrawn.) The rejection of Claim 7 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, is withdrawn in light of the amendments to the claim. (Rejection maintained.) Claim 8 remains rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 8 contains the trademark/trade name CEVEC®. Where a trademark or trade name is used in a claim as a limitation to identify or describe a particular material or product, the claim does not comply with the requirements of 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph. See Ex parte Simpson, 218 USPQ 1020 (Bd. App. 1982). The claim scope is uncertain since the trademark or trade name cannot be used properly to identify any particular material or product. A trademark or trade name is used to identify a source of goods, and not the goods themselves. Thus, a trademark or trade name does not identify or describe the goods associated with the trademark or trade name. In the present case, the trademark/trade name CEVEC® is a proprietary brand name and registered trademark of CEVEC Pharmaceuticals GmbH (Germany), and is used to identify/describe proprietary chemical/biological products, cell lines, polypeptides, proteins, and viral vectors and, accordingly, the identification/description is indefinite. Response to Arguments Applicant's arguments filed 07/27/2026 have been fully considered but they are not persuasive. While the original trademarked names have been removed, the use of CEVEC® creates an additional issue as CEVEC® is also a registered trademark. Therefore, claim 8 remains rejected. (Rejection withdrawn.) The rejection of Claim 11 and dependent claims 12-13 thereof under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, is withdrawn in light of the amendments to the claims. (Rejection withdrawn.) The rejection of Claims 14-16 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, is withdrawn in light of the amendments to the claims. Claim Interpretation The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. Claim 1 is drawn to a method for the production of Adeno-associated virus (AAV) in an isolated host cell, comprising the step of recombinantly expressing AAV Rep proteins Rep78 and Rep68 in a host cell using a first nucleic acid, wherein the proteins Rep78 and Rep68 are operably linked to an inducible promoter, wherein the internal AAV promoter p19 has one or more mutations selected from a p19 SP1, a p19 TATA, a p19 CGT, and a p19 CArG, wherein the internal AAV promoter p19 is inactivated and the functionality of said Rep78 and Rep68 proteins is maintained. Further limitations on the method of claim 1 are wherein said one or more mutations comprise at least one mutation, selected from the group consisting of mutations 731C>D, 732A>C, 734A>B 737T>C 746A>G 749C>D 752G>H 758G>A 761G>H 764G>H 818G>A 824G>H 830T>V 833T>C 845T>C 846T>C 8484A>B 848A>G 849A>T 850G>C and 851C>D, wherein the nucleotide positions are numbered according to SEQ ID NO:29 (claim 2); wherein said first nucleic acid comprises at least one nucleotide sequence, selected from the group consisting of the nucleotide sequences according to SEQ ID NOs: 1 to 8, 11 to 14, 34 to 35, and 37 to 42 (claim 3); wherein said first nucleic acid comprises at least one nucleotide sequence, selected from the group consisting of the nucleotide sequences according to SEQ ID NOs: 15 to 22, 25 to 28, 43 to 44, and 46 to 51 (claim 4); wherein said first nucleic acid comprises at least one nucleotide sequence, selected from the group consisting of the nucleotide sequences according to SEQ ID NOs: 9 and 10 (claim 5); wherein said first nucleic acid comprises at least one nucleotide sequence, selected from the group consisting of the nucleotide sequences according to SEQ ID NOs: 23 and 24 (claim 6); further comprising encoding AAV Rep proteins Rep52 and Rep40 using a second nucleic acid under the control of a heterologous, inducible promoter (claim 7); selected from the group consisting of CEVEC's Amniocyte Production cells, HEK293 cells, and primary embryonic retinal cells immortalized with adenovirus type-5 (Ad5) E1A and E1B genes (claim 8); wherein said nucleic acid is stably integrated into the host cell genome or is comprised in a vector (claim 9); wherein said nucleic acid is stably integrated into the host cell genome (claim 10); wherein said one or more mutations are within at least one of the two or more p19 promoter SP 1 sites or the two or more p19 TATA sites (claim 11), wherein said one or more mutations are within the two or more p19 promoter SP 1 sites (claim 12), wherein said one or more mutations are within the two or more p19 TATA sites (claim 13); wherein the one or more mutations includes a substitution at position 824 to an adenine, a cytosine, or a thymine, wherein the position 824 is numbered according to SEQ ID NO: 29 (claim 14); wherein the one or more mutations includes at least one substitution to cytosine at position 845, from thymine to cytosine at position 846, to cytosine, thymine, or guanine at position 848, or to thymine at position 849, wherein the nucleotide position is numbered according to SEQ ID NO: 29 (claim 15); and wherein the internal AAV promoter p19 comprises a substitution at position 818 to an adenine wherein the position 818 is numbered according to SEQ ID NO: 29 (claim 16). Claim Rejections - 35 USC § 112(a); First Paragraph The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. (Rejection maintained.) Claims 1-16 remain rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for methods of generating AAV5 using a CAP™ cell based system wherein the pStb1-bsd-TRE3G-Rep52/40-IRES-Rep78/68 plasmid comprises specific, limited mutations in p19 and Rep78/68 and Rep52/40 are both operably linked to a TRE3G (Tet-inducible) promoter, does not reasonably provide enablement for methods of generating any AAV in any cell type wherein there are any p19 mutations that allow any functionality of Rep78 and Rep68 to be retained. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims. The rationale behind this rejection was set forth in a previous Office action and will not be repeated herein. Response to Arguments Applicant's arguments filed 07/27/2026 have been fully considered but they are not persuasive. Applicant argues that claim 1 does not encompass an AAV having any mutation within the p19 promoter, but instead limits the mutation to one or more mutations selected from the p19 SP1, p19 TATA, p19 CGT, and p19 CArG regulatory regions. However, recitation of four regulatory regions does not limit the claim to four particular mutations or otherwise define the structure of the mutations encompassed by the claim. Rather, claim 1 continues to encompass an unspecified mutation, or combination of mutations, within any of these regulatory regions, provided that the mutation both inactivated the internal p19 promoter and maintains the functionality of Rep78 and Rep68. The claimed genus is therefore defined substantially by the functional results to be achieved rather than by the particular mutations disclosed in the specification. The specification provides particular nucleotide substitutions and combinations thereof and experimentally evaluates selected constructs. However, the experimental results do not establish that mutations throughout each of the four presently claimed regulatory regions predictably provide the two claimed functional properties. To the contrary, the specification reports that only “most” tested mutation patterns significantly reduced expression of the short Rep proteins, identifies certain regulatory regions and particular mutations as having more pronounced effects than others, and reports that for at least one regulatory region, a combination of mutations was required to obtain a clear decrease in expression. Accordingly, the disclosed results demonstrate that the effect of a particular mutation on p19 activity cannot be determined merely from its location within one of the recited regulatory regions. A person of ordinary skill would therefore be required to generate candidate mutations within the claimed regulatory regions and empirically determine, for each candidate or combination of candidates, whether the mutation sufficiently inactivates p19 while also preserving the functionality of Rep78 and Rep68 and permitting the claimed production of AAV. The ability of a skilled artisan to make mutations and assay their effects does not, by itself, establish enablement of the full scope of a functionally defined genus. See MPEP§ 2164.01(a), 2164.02, and 2164.08. The relevant inquiry is whether the specification teaches the skilled artisan to make and use the full scope of the claimed invention without undue experimentation, not merely whether individual candidates can be generated and screened. Moreover, claim 1 is not limited to the specific nucleotide substitutions, mutation patterns, or SEQ ID NOs shown to possess the claimed properties, nor is claim 1 limited to AAV2. The amendment requiring production in an isolated host cell and recombinant expression of Rep78 and Rep68 from a first nucleic acid does not cure this deficiency because it does not materially limit the breadth of the p19 mutation genus or provide additional guidance permitting the skilled artisan to predict which mutations throughout that genus will satisfy the claimed functional requirements. Accordingly, Applicant’s arguments are unpersuasive, and the rejection is maintained. (Rejection withdrawn.) The rejection of Claims 1-16 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for methods of generating AAV in an isolated host cell, does not reasonably provide enablement for performing said method in any host cell within a transgenic animal, or in order to generate a transgenic animal, is withdrawn in light of the amendments to the claims. (Rejection maintained.) Claims 1-16 remain rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The rationale behind this rejection was set forth in a previous Office action and will not be repeated herein. Response to Arguments Applicant's arguments filed 07/27/2026 have been fully considered but they are not persuasive. Applicant argues that claim 1 is adequately described because the claim is limited to mutations within the p19 SP1, p19 TATA, p19 CGT, and p19 CArG regulatory regions, and because the specification describes the structure and corresponding function of AAVs containing such mutations. However, identifying the regulatory regions in which a mutation may occur is not equivalent to describing the presently claimed genus of mutations. Claim 1 does not recite the particular nucleotide substitutions or mutation patterns disclosed in the specification. Instead, it encompasses any one or more mutations within the four recited regulatory regions that satisfy the functional requirements that the p19 promoter be inactivated while the functionality of Rep78 and Rep68 is maintained. Therefore, the relevant written description inquiry is whether the specification demonstrates possession of that broader genus, rather than merely possession of the particular mutation patterns expressly disclosed and tested. The specification describes numerous specific nucleotide substitutions and selected combinations thereof, but the disclosed results show substantial variation in the effect of those mutations. The specification identifies particular mutations as producing especially pronounced effects and indicates that mutation of different regulatory elements produces different degrees of suppression of short Rep expression. Such results do not establish a general structural characteristic common to mutations throughout each of the four claimed regulatory regions from which the skilled artisan would recognize that the inventors possessed the full genus of mutations satisfying both claimed functions. A genus may be adequately described by a representative number of species or by disclosure of structural features coupled with a known or disclosed correlation between structure and function. See MPEP § 2163. Applicant has not established that merely locating a mutation within SP1, TATA, CGT, or CArG provides such a structure-function correlation. Knowledge in the art concerning the location, nomenclature, or regulatory significance of the CGT and CArG elements may establish that mutations generally within those elements will both inactivate p19 and preserve functional Rep78 and Rep68. Accordingly, Applicant’s arguments concerning the meaning and recognition of the recited regulatory elements do not remedy the separate written description deficiency. The amendment requiring that the AAV be produced in an isolated host cell using a first nucleic acid for recombinant expression of Rep78 and Rep68 likewise does not provide written description support for the breadth of the claimed p19 mutation genus. Applicant has therefore not shown that the specification reasonably conveys to a person of ordinary skill that the inventors were in possession, at the time of filing, of the full scope of mutations encompassed by claim 1. For at least these reasons, the arguments are not persuasive, and the rejection has been maintained. Double Patenting The text regarding nonstatutory double patenting was presented in a previous Office action. (Rejection maintained.) Claims 1-16 remain rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-10 of U.S. Patent No. 11,685,932. The rationale behind this rejection was set forth in a previous Office action and will not be repeated herein. (Rejection maintained.) Claims 1-16 remain rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-17 of U.S. Patent No. 12,060,569. The rationale behind this rejection was set forth in a previous Office action and will not be repeated herein. Response to Arguments Applicant's arguments filed 07/27/2026 have been fully considered but they are not persuasive. Applicant has requested that the non-statutory obviousness-type double patenting rejection be held in abeyance until allowable subject matter is indicated in the present application. However, said rejection must be maintained as a matter of record until the appropriate terminal disclaimers have been filed, or until the claims have been amended in such a way as to not claim patently identical subject matter. Allowable Subject Matter The following is a statement of reasons for the indication of allowable subject matter: SEQ ID NOs: 1-8, 11-22, 25-28, 34-35, 37-44, and 46-51 appear to only be disclosed in the parent patents. Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RACHEL B GILL whose telephone number is (571)272-3129. The examiner can normally be reached on M to F 8:00 AM to 5:00 PM Eastern. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Allen can be reached on (571) 270-3497. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RACHEL B GILL/ Primary Examiner, Art Unit 1648
Read full office action

Prosecution Timeline

Jul 16, 2024
Application Filed
Apr 29, 2026
Non-Final Rejection mailed — §112, §DP
Jul 27, 2026
Response Filed
Sep 23, 2026
Final Rejection mailed — §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779032
ADOPTIVE IMMUNOTHERAPY
4y 6m to grant Granted Nov 03, 2026
Patent 12781290
Primers and Probes and Reagent Kit for Synchronous Detection of CymMV, ORSV, and CymRSV, and Applications Thereof
2y 10m to grant Granted Nov 03, 2026
Patent 12752002
POLYPEPTIDES, COMPOSITIONS, AND THEIR USE TO TREAT OR LIMIT DEVELOPMENT OF AN INFECTION
3y 10m to grant Granted Oct 06, 2026
Patent 12747268
HIGH-POTENCY SARS CORONAVIRUS 2 ANTIGEN AND VACCINE COMPOSITION COMPRISING SAME
3y 10m to grant Granted Sep 29, 2026
Patent 12714733
SEQUENTIAL HETEROLOGOUS BOOST ONCOLYTIC VIRAL IMMUNOTHERAPY
4y 11m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
66%
Grant Probability
94%
With Interview (+28.6%)
Moderate
PTA Risk
Based on 889 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month